Pricing Log in Create free account

Agenus Inc. (AGEN) vs Galectin Therapeutics Inc. (GALT)

Agenus Inc. and Galectin Therapeutics Inc. are both Biotechnology companies. Agenus Inc. and Galectin Therapeutics Inc. are of similar size ($301.0M and $290.8M). Galectin Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; Agenus Inc. trades at 10.7×. Agenus Inc. has the higher net margin (22.0% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Agenus Inc. leads on 7 and Galectin Therapeutics Inc. on 5.

Valuation

Metric AGEN GALT Biotechnology median
P/E 10.70 n/m 10.60
P/S 3.33 n/m 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 7.99 n/m 0.66
EV/Sales 3.24 n/m 9.02
Earnings yield 9.35% (13.69%) (32.88%)
Free cash flow yield (23.17%) (7.68%) (23.13%)

Profitability

Metric AGEN GALT Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin 38.94% 0.00% 0.00%
Net margin 21.99% 0.00% 0.00%
Free cash flow margin (77.54%) 0.00% 0.00%
Return on equity (14.99%) 21.69% (51.96%)
Return on assets 12.29% (184.22%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AGEN GALT Biotechnology median
Revenue growth (TTM) 25.38% — 6.76%
EPS growth (last fiscal year) 100.00% 36.84% 29.88%
Revenue growth, 5-year CAGR 5.31% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AGEN GALT Biotechnology median
Debt to equity (0.22) (0.76) 0.00
Current ratio 0.73 0.10 4.97
Net debt to EBITDA (4.10) (5.79) 1.01

Dividend

Metric AGEN GALT Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AGEN GALT Biotechnology median
Market cap 290.84m 301.04m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack